Theravance Biopharma is a biopharmaceutical company with one approved product that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.

Biotechnology

Theravance

Andrew Hindman is the Senior Vice President and Chief Financial Officer at [Theravance](/org/theravance). Prior to joining [Theravance](/org/theravance), they served as the Chief Business Officer of [Acorda Therapeutics](/org/acorda-therapeutics) from 2014 to 2019. From 2013 to 2014, they were a Board Member of the Biotechnology Industry Organization. From 2011 to 2014, they were the President and Chief Executive Officer of Tobira Therapeutics. From 2010 to 2011, they were the Senior Vice President of Corporate Development at Nodality Inc. From 2008 to 2010, they were the Vice President of Corporate Development at Onyx Pharmaceuticals. From 1998 to 2008, they were the Senior Director at [Gilead Sciences](/org/gilead-sciences). Prior to [Gilead Sciences](/org/gilead-sciences), they worked as an Associate-Healthcare Investment Banking at J.P. Morgan from 1995 to 1998.

Andrew Hindman received their MBA from Columbia Business School, where they studied finance. Andrew also holds a BA from [Wesleyan University](/org/wesleyan-university) in biochemistry and economics. In addition, they have completed [Harvard Business School](/org/harvard-business-school)'s Leadership and Strategy in Pharma & Biotech Program.

Andrew Hindman reports to Rick E Winningham, Chairman & CEO . They are on a team with Richard A. Graham - SVP, Research & Development, Kenneth R. Pitzer - Senior Vice President, Product Strategy and Commercial Planning, and Rhonda Farnum - Vice President, Sales & Marketing.

Andrew Hindman

Since 2001, Dr. Pakianathan has served as a Managing Member at Delphi Ventures, a venture capital firm. From 2007 to 2019, Dr. Pakianathan served on the board of directors of Alder Pharmaceuticals, Inc. and from 2004 to 2016, Dr. Pakianathan served on the board of directors of Alexza Pharmaceuticals, Inc. From 1998 to 2001, Dr. Pakianathan served as a Vice President in the healthcare group at JP Morgan Chase & Company. From 1993 to 1997, Dr. Pakianathan served as a postdoctoral scientist in the Immunology Department at Genentech Corporation.

Dr. Pakianathan currently serves on the board of directors of Calithera Biosciences, Inc., Karyopharm Therapeutics, Inc., and Mereo Biopharma Group PLC.

Dr. Pakianathan holds an M.S. and a Ph.D. from [Wake Forest University](/org/wake-forest-university), a B.Sc. from the University of Bombay, India and an M.Sc. from The Cancer Research Institute at the University of Bombay, India. 

Deepa R. Pakianathan

William D. Young has served as a director since October 2013 and has served as the lead independent director since April 2014. Prior to thereavance's spin-off from Innoviva in June 2014 and since April 2001, Mr. Young served as a director of Innoviva.

He has been a Senior Advisor of Blackstone Life Sciences since 2018, when Blackstone Life Sciences acquired Claris Ventures. He was a Venture Partner at Claris Ventures from 2010 until 2018.

Mr. Young served from 1999 until 2009 as Chairman of the board of directors and Chief Executive Officer of Monogram Biosciences, Inc., a biotechnology company. From 1980 to 1999 Mr. Young was employed at Genentech, Inc., most recently as Chief Operating Officer, where he was responsible for all Product Development, Manufacturing and Commercial functions.

Prior to joining Genentech, Mr. Young worked at Eli Lilly and Company for 14 years. Mr. Young has been Chairman of NanoString Technologies, a biotechnology company, since 2010, and of Annexon Biosciences, a biotechnology company and Clarus portfolio company, since March 2017.

In addition, Mr. Young is a member of the board of directors of Praxis Precision Medicine, a public company, and SFJ Pharmaceuticals, both Clarus portfolio companies. He was a member of the board of directors of Vertex Pharmaceuticals until June 2020, BioMarin, Inc. until October 2015, and Biogen Idec Inc. until June 2014, having served as a director since 1997 and as Chairman of the Board since 2010. Mr. Young is also a Trustee of Montage Health, a nonprofit company.

Mr. Young received his M.B.A. from Indiana University and his B.S. in Chemical Engineering from Purdue University, and an honorary Doctorate of Engineering from Purdue University. Mr. Young was elected to The National Academy of Engineering in 1993 for his contributions to biotechnology.

William S. Beinecke

Richard A. Graham, Ph.D.,  was appointed Senior Vice President, Development in August 2020, where he is responsible for leading the progression of late-stage clinical assets through regulatory filing and approval. Since joining Theravance Biopharma, Dr. Graham has served as Vice President of Clinical Pharmacology, and more recently, as Vice President of Clinical Development.

Prior to joining Theravance Biopharma, Dr. Graham spent five years at GlaxoSmithKline working in the area of Drug Metabolism and Pharmacokinetics, seven years at Genentech/Roche as a clinical pharmacologist and Global Development Team Leader, and one year at Onyx Pharmaceuticals where he headed Translational Medicine. In his nearly 20-year career, he worked across all stages of drug development and all major therapeutic areas.

Dr. Graham received his Bachelor’s and Master’s degree in Biochemistry from [Iowa State University](/org/iowa-state-university) and his Doctorate of Philosophy degree in Pharmaceutical Sciences from The University of North Carolina at Chapel Hill.

Theravance

About

Photos

Values

Insider experiences

Org chart

Teams

Jobs

Wires

Similar organizations